Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Scientific and Technological Prospecting on Polymeric Particles Containing Extracellular Matrix Peptides for the Treatment of Duchenne Muscular Dystrophy.
Recent Adv Drug Deliv Formul
January 2025
Laboratory of Innovation in Science and Technology - LACITEC, Department of Biophysics and Physiology, Federal University of Piauí, Teresina, Piauí, PI, Brazil.
Duchenne muscular dystrophy is a neuromuscular disease with an overall incidence of between 1 in 5,000 newborn males. Carriers may manifest progressive muscle weakness, resulting from the progressive degeneration of skeletal muscles, generating cardiac and respiratory disorders. Considering the lack of effective treatments, different therapeutic approaches have been developed, such as protein synthesis and extracellular matrix derivatives that can be used to improve muscle regeneration, maintenance, or repair.
View Article and Find Full Text PDFLow-dose Systemic Tissue-type-plasminogen-activator Compared to Conventional Anti-coagulation for the Treatment of Intermediate-high Risk Pulmonary Embolism.
Cardiovasc Hematol Disord Drug Targets
January 2025
Division of Pulmonary and Critical Care Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Background: Pulmonary embolism (PE) is a frequent cause of death. Acute PE may be treated either with full anticoagulation (AC) alone or thrombolytic therapy with systemic tissue-- type-plasminogen-activator (tPA) based on risk assessment. Currently, AC is the standard of care for most patients with intermediate-high-risk PE, with low-dose tPA emerging as an effective alternative.
View Article and Find Full Text PDFA pilot human study using ketamine to treat disorders of consciousness.
iScience
January 2025
Coma Science Group, GIGA-Consciousness, University of Liège, Liège, Belgium.
Post-comatose disorders of consciousness (DoC) represent persistent neurological conditions with limited therapeutic options and a poor prognosis. Recent works advocate for exploring the effects of psychedelics to enhance brain complexity in DoC and ameliorate their consciousness. We investigated sub-anesthetic concentration of the atypical psychedelic ketamine for treating post-comatose prolonged DoC through a double-blind, placebo-controlled, cross-over trial involving three adult patients.
View Article and Find Full Text PDFNeutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Predicts the Disease Activity in Patients with Paediatric Systemic Lupus Erythematosus: An Observational Cross-Sectional Study.
Mediterr J Rheumatol
December 2024
Department of Paediatric Medicine.
Background: To assess the association between Neutrophil-to-lymphocyte ratio (NLR) and Platelet-to-lymphocyte ratio (PLR) with a degree of activity of paediatric systemic lupus erythematosus (pSLE) in terms of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score.
Methods: This observational cross-sectional study was conducted in Paediatric Rheumatology Clinic, Medical College Kolkata. Systemic lupus erythematosus was diagnosed in children based on the 2019 EULAR/ACR criteria and/or SLICC 2012 criteria.
Hypoxia and hypotension following industrial-grade anhydrous ethanol ablation of the vein of Marshall in the treatment of atrial fibrillation: a case report.
Pan Afr Med J
January 2025
Cardiovascular Department, The Affiliated People´s Hospital of Ningbo University, Ningbo, 315000, ZheJia, China.
This case presents a patient who experienced hypoxia and hypotension following the infusion of industrial-grade anhydrous ethanol into the vein of Marshall (VOM) during atrial fibrillation radiofrequency ablation. The hypotension lasted for at least three days, requiring dopamine support, while hypoxia persisted for over a week. The prolonged nature of these symptoms posed a diagnostic challenge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!